Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting (APORIAS)

NCT01163604 Phase 4 COMPLETED Results posted

Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis post cranial stenting. This study will test the safety and efficacy of the argatroban on prevent occlusion and restenosis in patients with intracranial and extracranial artery stenting.

Details

Lead sponsor	Jinling Hospital, China
Phase	Phase 4
Status	COMPLETED
Enrolment	114
Start date	2010-08
Completion	2014-08

Conditions

• CVD

Interventions

• Argatroban
• non-argatroban treated group

Primary outcomes

• Number of Participants With Occlusion and Restenosis at One Year — at one year
  Stenosis detected by DSA(digital subtraction angiography),CTA(CT angiography)or MRA(MR angiography)was measured according to NASCET(North American Symptomatic Carotid Endarterectomy Trial)method.Concretely, NASCET stenosis is calculated from the ratio of the linear luminal diameter of the narrowest segment of the diseased portion of the artery to the diameter of the artery beyond any poststenotic dilatation: NASCET=(1-md/C)×100%

Countries

China